- Home
- FULC vs MCI Comparison
FULC vs MCI Comparison
Compare FULC & MCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULC
- MCI
- Stock Information
- Founded
- FULC 2015
- MCI 1971
- Country
- FULC United States
- MCI United States
- Employees
- FULC N/A
- MCI N/A
- Industry
- FULC Biotechnology: Pharmaceutical Preparations
- MCI Trusts Except Educational Religious and Charitable
- Sector
- FULC Health Care
- MCI Finance
- Exchange
- FULC Nasdaq
- MCI Nasdaq
- Market Cap
- FULC 469.0M
- MCI 419.4M
- IPO Year
- FULC 2019
- MCI N/A
- Fundamental
- Price
- FULC $9.02
- MCI $20.56
- Analyst Decision
- FULC Buy
- MCI
- Analyst Count
- FULC 7
- MCI 0
- Target Price
- FULC $10.43
- MCI N/A
- AVG Volume (30 Days)
- FULC 578.7K
- MCI 40.4K
- Earning Date
- FULC 10-29-2025
- MCI 01-01-0001
- Dividend Yield
- FULC N/A
- MCI 8.46%
- EPS Growth
- FULC N/A
- MCI N/A
- EPS
- FULC N/A
- MCI 1.82
- Revenue
- FULC N/A
- MCI N/A
- Revenue This Year
- FULC N/A
- MCI N/A
- Revenue Next Year
- FULC N/A
- MCI N/A
- P/E Ratio
- FULC N/A
- MCI $9.88
- Revenue Growth
- FULC 2752.05
- MCI N/A
- 52 Week Low
- FULC $2.32
- MCI $12.96
- 52 Week High
- FULC $10.11
- MCI $19.24
- Technical
- Relative Strength Index (RSI)
- FULC 51.00
- MCI 49.66
- Support Level
- FULC $8.42
- MCI $20.02
- Resistance Level
- FULC $10.09
- MCI $21.30
- Average True Range (ATR)
- FULC 0.82
- MCI 0.43
- MACD
- FULC -0.12
- MCI 0.11
- Stochastic Oscillator
- FULC 40.56
- MCI 52.12
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About MCI Barings Corporate Investors
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.